Dexmedetomidine

Generic Name: Dexmedetomidine

Brand Names: Dexdor, Igalmi, Precedex, Dexmedetomidine Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₂

CAS Number: 113775-47-6

Unique Ingredient Identifier: 67VB76HONO

Background: An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

Indication: Administered intravenously, dexmedetomidine is indicated for the sedation of initially intubated and mechanically ventilated patients during treatment in intensive care settings, and for the sedation of non-intubated patients prior to and/or during surgery and other procedures. It is also available as a buccally- or sublingually-administered dissolvable film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.

Associated Conditions: Agitation, Alcohol Withdrawal Syndrome

Associated Therapies: -

Clinical Trials

Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep

Not Applicable

Completed

Conditions: Dexmedetomidine Induced Sedation

Interventions: Drug: dexmedetomidine

First Posted Date: 2011-12-05

Last Posted Date: 2019-01-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT01485380

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Dexmedetomidine in Patients After Intracranial Surgery

Phase 4

Completed

Conditions: Central Nervous System Diseases

Interventions: Drug: Normal saline
Drug: Dexmedetomidine

First Posted Date: 2011-10-04

Last Posted Date: 2014-01-28

Lead Sponsor: Capital Medical University

Target Recruit Count: 192

Registration Number: NCT01445639

Locations: 🇨🇳
Neuro-ICU, Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

Study to Determine if the Midazolam-Meperidine-Dexmedetomidine is Superior to the Midazolam-Meperidine for Sedation During ERCP

Phase 4

Completed

Conditions: Undergoing ERCP for Diagnostic or Therapeutic Purposes

Interventions: Other: normal saline
Drug: Dexmedetomidine

First Posted Date: 2011-07-28

Last Posted Date: 2013-07-16

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 110

Registration Number: NCT01404689

Locations: 🇰🇷
Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

Safety Evaluation of Dexmedetomidine for EBUS-TBNA

Phase 4

Conditions: Lung Cancer

Interventions: Drug: Remifentanil
Drug: Dexmedetomidine

First Posted Date: 2011-06-27

Last Posted Date: 2013-02-28

Lead Sponsor: Maisonneuve-Rosemont Hospital

Target Recruit Count: 60

Registration Number: NCT01381627

Locations: 🇨🇦
Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months

Phase 2

Completed

Conditions: Sedation
Pain

Interventions: Drug: Dexmedetomidine

First Posted Date: 2011-06-23

Last Posted Date: 2015-07-24

Lead Sponsor: Hospira, now a wholly owned subsidiary of Pfizer

Target Recruit Count: 5

Registration Number: NCT01378988

Locations: 🇺🇸
Children's Hospital of Pittusburgh of UPMC, Pittsburgh, Pennsylvania, United States

Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care

Not Applicable

Completed

Conditions: Delirium
Cardiac Disease

Interventions: Drug: Dexmedetomidine
Drug: Propofol

First Posted Date: 2011-06-22

Last Posted Date: 2015-04-21

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 185

Registration Number: NCT01378741

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

ED50 of Dexmedetomidine to Prevent Emergence Agitation in Children

Phase 4

Conditions: Agitation

Interventions: Drug: Dexmedetomidine

First Posted Date: 2011-06-16

Last Posted Date: 2011-06-16

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 25

Registration Number: NCT01374737

Locations: 🇰🇷
SNUH, Seoul, Korea, Republic of

The Effect of Dexmedetomidine on Postoperative Analgesia

Phase 4

Completed

Conditions: Colon Cancer, Rectal Cancer

Interventions: Drug: Fentanyl
Drug: Dexmedetomidine

First Posted Date: 2011-06-14

Last Posted Date: 2012-03-08

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 95

Registration Number: NCT01373021

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

Phase 4

Terminated

Conditions: Alcohol Withdrawal-Induced Delirium Tremens
Alcohol Withdrawal Delirium
Alcohol Withdrawal Associated Autonomic Hyperactivity
Alcohol Withdrawal Hallucinosis

Interventions: Drug: Placebos
Drug: Dexmedetomidine

First Posted Date: 2011-05-30

Last Posted Date: 2017-11-06

Lead Sponsor: Denver Health and Hospital Authority

Target Recruit Count: 49

Registration Number: NCT01362205

Locations: 🇺🇸
St. Anthony Hospital, Lakewood, Colorado, United States
🇺🇸
Porter Adventist Hospital, Denver, Colorado, United States
🇺🇸
Memorial Hospital Central, Colorado Springs, Colorado, United States

and more 4 locations

Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery

Phase 3

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Dexmedetomidine
Drug: Normal Saline

First Posted Date: 2011-05-13

Last Posted Date: 2013-04-04

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 100

Registration Number: NCT01353456

Locations: 🇨🇳
Queen Mary Hosspital, Hong Kong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy